| Literature DB >> 30845653 |
Nathaniel M Byers1, Amy C Fleshman2, Rushika Perera3, Claudia R Molins4.
Abstract
The global burden of arboviral diseases and the limited success in controlling them calls for innovative methods to understand arbovirus infections. Metabolomics has been applied to detect alterations in host physiology during infection. This approach relies on mass spectrometry or nuclear magnetic resonance spectroscopy to evaluate how perturbations in biological systems alter metabolic pathways, allowing for differentiation of closely related conditions. Because viruses heavily depend on host resources and pathways, they present unique challenges for characterizing metabolic changes. Here, we review the literature on metabolomics of arboviruses and focus on the interpretation of identified molecular features. Metabolomics has revealed biomarkers that differentiate disease states and outcomes, and has shown similarities in metabolic alterations caused by different viruses (e.g., lipid metabolism). Researchers investigating such metabolomic alterations aim to better understand host⁻virus dynamics, identify diagnostically useful molecular features, discern perturbed pathways for therapeutics, and guide further biochemical research. This review focuses on lessons derived from metabolomics studies on samples from arbovirus-infected humans.Entities:
Keywords: alphavirus; arbovirus; flavivirus; lipid; metabolism; metabolomics
Mesh:
Year: 2019 PMID: 30845653 PMCID: PMC6466193 DOI: 10.3390/v11030225
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Workflow for metabolomic studies. Samples used for metabolomics analyses, most commonly serum or urine, should be carefully collected, stored, and characterized to confirm infection status and group membership. Metabolites are then quenched and extracted for nuclear magnetic resonance (NMR) or mass spectrometry (MS) analyses. Common MS techniques include direct-injection mass spectrometry (DIMS), liquid chromatography–mass spectrometry (LC-MS) and gas chromatography–mass spectrometry (GC-MS). Analytical methods generate data that must be aligned, extracted, corrected, and filtered to obtain molecular features. Metabolite identification and pathway analyses provide insight into the pathways perturbed during a disease state. Statistical analyses, such as principal component analysis (PCA) and partial least squares discriminate analysis (PLS-DA), differentiate and further classify samples and identify potential biomarker candidates. Once pathways and potential biomarkers have been elucidated, secondary verifications, such as targeted analyses, are often performed to confirm and further investigate biological connections, modes of action, or therapeutic potential of identified biomarkers.
Figure 2Lipid structures. LIPID MAPS naming conventions indicate “carbon atoms”: “double bonds” (location and conformation of double bonds) [80]. Phosphatidylcholine (PC) is composed of two lipid tails esterified to glycerol 3-phosphate with a choline head group. Glycerol’s stereospecific carbons are numbered sn-1, sn-2, and sn-3 [81]. Phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylinositol (PI) have the same structure, but with alternative head groups. Ceramide (Cer) contains a sphingosine backbone, and a fatty acyl group. Sphingomyelin is Cer with a phosphocholine or phosphoethanolamine head group. The “d” in the name indicates that these have 1,3-dihydroxy sphingosine backbones.
Metabolite abbreviations. Other abbreviations are listed at the end of the text.
| Abbreviation | Metabolite |
|---|---|
| AA | arachidonic acid |
| ALA | α-linolenic acid |
| ATP | adenosine triphosphate |
| Cer | ceramide |
| DGLA | dihomo-γ-linolenic acid |
| DHA | docosahexaenoic acid |
| DHCer | dihydroceramide |
| EPA | eicosapentaenoic acid |
| FADH2 | flavin adenine dinucleotide |
| GTP | guanosine triphosphate |
| LPC | lysophosphatidylcholine |
| LPE | lysophosphatidylethanolamine |
| LPI | lysophosphatidylinositol |
| LPL | lysophospholipid |
| LPS | lysophosphatidylserine |
| NADH | nicotinamide adenine dinucleotide |
| PC | phosphatidylcholine |
| PE | phosphatidylethanolamine |
| PG | phosphatidylglycerol |
| PI | phosphatidylinositol |
| PIP | phosphatidylinositol phosphate |
| p-PC | plasmalogen phosphatidylcholine |
| p-PE | plasmalogen phosphatidylethanolamine |
| PS | phosphatidylserine |
| SM | sphingomyelin |
| VLDL/LDL | very-low-density lipoprotein/low-density lipoprotein |
Selected metabolites from publications on human infections with dengue viruses (DENVs). Metabolites generally increased in disease are in red, decreased metabolites are in blue. Black metabolites have mixed results in the corresponding publication. If not specified, LC was reversed-phase. Standard single letter amino acid abbreviations are used.
| Publication | Arboviruses Studied | Sample Source | Technique | Comparison | Selected Metabolites ( | Ref. No. |
|---|---|---|---|---|---|---|
| Cui et al., 2013 | DENV1–3 (mostly DENV1 and DENV3) | Human sera | LC-MS; GC-MS; MRM | healthy vs 3 DF time points | [ | |
| Voge et al., 2016 | DENV2 and DENV1 | Human sera | HILIC-MS; LC-MS/MS; MRM | non-dengue vs DF vs DHF/DSS | [ | |
| Cui et al., 2016 | DENV1–4 (mostly DENV2) | Human sera | LC-MS; LC-MS/MS; MRM | DF vs DHF | [ | |
| Cui et al., 2018 | DENV1–4 (mostly DENV2) | Human sera | LC-MS; LC-MS/MS | DF vs DHF | [ | |
| Khedr et al., 2015 | DENV | Human blood | GC-MS | healthy vs early febrile DF | [ | |
| Khedr et al., 2016 | DENV | Human sera | LC-MS/MS | healthy vs DF | [ | |
| El-Bacha et al., 2016 | DENV3 | Human sera | 1H NMR | non-Dengue vs primary DF; secondary DF; primary DHF; secondary DHF | amino acids (A; H; | [ |
| Villamor et al., 2018 | DENV1–4 | Human sera | GC-MS | DF vs DHF | [ | |
| Melo et al., 2018 | DENV4 | Human sera | DIMS; MS/MS | healthy vs DF | [ | |
| Shahfiza et al., 2017 | DENV | Male human urine | 1H NMR | healthy vs DF | [ |
Selected metabolites from papers on infection with DENVs in model systems and mosquitoes. Metabolites generally increased in disease are in red, decreased metabolites are in blue. Black metabolites have mixed results in the corresponding publication. If not specified, LC was reversed-phase. Standard single letter amino acid abbreviations are used.
| Publication | Arboviruses Studied | Sample Source | Technique | Comparison | Selected Metabolites ( | Ref. No. |
|---|---|---|---|---|---|---|
| Cui et al., 2017 | DENV2 | Humanized mouse sera | HILIC and RPLC-MS; LC-MS/MS | DENV2 time points (0, 3, 7, 14, & 28 days post infection (dpi)) | [ | |
| Brooks et al., 1983 | DENV1–4 | Monkey kidney cell media | Frequency-pulsed electron-capture gas-liquid chromatography | mock vs DENV1–4 | [ | |
| Birungi et al., 2010 | DENV1–4 | human endothelial cell media | 1H NMR; DIMS | mock vs DENV1–4 (6, 24, & 48 hpi) | [ | |
| Fontaine et al., 2015 | DENV2 | Human foreskin fibroblast cell lysate | GC-MS; LC-MS | mock vs DENV2 (10, 24, & 48 hpi) | amino acids (A; | [ |
| Perera et al., 2012 | DENV2 | C6/36 | LC-MS; MRM | mock and UV-inactivated DENV2 vs DENV2 | [ | |
| Chotiwan et al., 2018 | DENV2 | LC-MS; LC-MS/MS; MRM | mock vs DENV2 (3, 7, & 11 dpi) | glycerophospholipids (LPC; LPE; | [ |
Figure 3Fatty acid metabolism. Fatty acids are freed from glycerophospholipids by phospholipases producing lysophospholipids (LPL). Fatty acids are then conjugated to coenzyme A (CoA). The fatty acyl is bonded to carnitine for transport to the mitochondrial matrix, where they can undergo β-oxidation generating acetyl-CoA. The acetyl-CoA can enter the tricarboxylic acid (TCA) cycle to generate NADH which will produce adenosine triphosphate (ATP) during oxidative phosphorylation, or the acetyl-CoA can be used to build new fatty acids and glycerophospholipids. The fatty acids can also be used to remodel glycerophospholipids in the Lands’ cycle without being degraded [98].
Selected metabolites from papers on chikungunya virus (CHIKV), West Nile virus (WNV), and Zika virus (ZIKV). Metabolites generally increased in disease are in red, decreased metabolites are in blue. Black metabolites have mixed results in the corresponding publication. If not specified, LC was reversed-phase. Standard single letter amino acid abbreviations are used.
| Publication | Arboviruses Studied | Sample Source | Technique | Comparison | Selected Metabolites ( | Ref. No. |
|---|---|---|---|---|---|---|
| Shrinet et al., 2016 | DENV and CHIKV | Human sera | 1H NMR | Healthy vs CHIKV vs DENV vs co-infected | carbohydrates (sorbitol); amino acids (Q); pyrimidine; organic acids | [ |
| Martin-Acebes et al., 2014 | WNV | HeLa cell lysate | LC-MS; LC-Orbitrap | mock vs WNV | [ | |
| Merino-Ramos et al., 2016 | WNV | Vero cell lysate | LC-MS | WNV infected vs WNV infected treated with ACC inhibitor | [ | |
| Liebscher et al., 2018 | WNV | Vero cell lysate | LC-MS/MS | mock vs WNV | glycerophospholipids ( | [ |
| Melo et al., 2016 | ZIKV | C6/36 | MALDI MS; MS/MS | mock vs ZIKV infected | [ | |
| Melo et al., 2017 | ZIKV | Human sera | DIMS | healthy and non-ZIKV vs ZIKV | [ |
Comparison of metabolic profiling, PCR, and serology techniques for assaying arbovirus infection.
| Metabolic Profiling | PCR | Serology | |
|---|---|---|---|
|
| Indirect | Direct | Indirect |
|
|
Mass spectrometers are found in hospital laboratories (particularly those linked to universities), major clinical laboratories and laboratories performing newborn screening Not commonly found in resource-limited settings |
Common to most clinical laboratories and becoming more accessible in resource-limited settings |
Common to most clinical laboratories including in resource-limited settings |
|
| Simple | Simple to difficult | Simple |
|
| Diagnostic and prognostic | Diagnostic | Diagnostic |
|
|
Requires advanced instrumentation Currently not being applied for infectious disease diagnostics Not standardized |
Laboratory contamination Dependent on viral load Specificity issues |
Dependent on adaptive immune response Cannot differentiate past from current infection Cross-reactivity |
|
|
Flexibility in adjusting specificity and sensitivity when monitoring multiple biomarkers Can measure rapid changes in metabolite abundance for monitoring disease progression High resolution |
Rapid Highly sensitive when virus load is sufficient |
Multiple platforms in diagnostic use Standardized |